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Background: Measures to improve the quality and sustainability of healthcare practice and provision have become
a policy concern. In addition, the involvement of stakeholders in health policy decision-making has been advocated,
as complex questions arise around the structure of funding arrangements in a context of limited resources. Using a
case study of assisted reproductive technologies (ART), deliberative engagements with a range of stakeholder
groups were held on the topic of how best to structure the distribution of Australian public funding in this domain.
Methods: Deliberative engagements were carried out with groups of ART consumers, clinicians and community
members. The forums were informed by a systematic review of ART treatment safety and effectiveness (focusing, in
particular, on maternal age and number of treatment cycles), as well as by international policy comparisons, and
ethical and cost analyses. Forum discussions were transcribed and subject to thematic analysis.
Results: Each forum demonstrated stakeholders’ capacity to understand concepts of choice under resource scarcity
and disinvestment, and to countenance options for ART funding not always aligned with their interests.
Deliberations in each engagement identified concerns around ‘equity’ and ‘patient responsibility’, culminating in a
broad preference for (potential) ART subsidy restrictions to be based upon individual factors rather than maternal
age or number of treatment cycles. Community participants were open to restrictions based upon measures of
body mass index (BMI) and smoking status, while consumers and clinicians saw support to improve these factors as
part of an ART treatment program, as distinct from a funding criterion. All groups advocated continued patient
co-payments, with measures in place to provide treatment access to those unable to pay (namely, equity of access).
Conclusions: Deliberations yielded qualitative, socially-negotiated evidence required to inform ethical, accountable
policy decisions in the specific area of ART and health care more broadly. Notably, reductionist, deterministic
characterizations of stakeholder ‘self-interest’ proved unfounded as each group sought to prioritise universal values
(in particular, ‘equity’ and ‘responsibility’) over specific, within-group concerns. Our results - from an emotive case
study in ART - highlight that evidence-informed disinvestment decision-making is feasible, and potentially less
controversial than often presumed.
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Internationally, measures to improve the quality and sus-
tainability of healthcare practice and provision have become
a key concern of policy [1]. As costs and service demands
increase against a background of limited resources, priority
setting has become a complex and increasingly central
component of healthcare policymaking. Within this
context, decisions must inevitably be made as to the
public reimbursement of new treatments and technologies
and the restriction of funding for established services [2].
An approach to the latter concern, ‘disinvestment’ has
emerged as a means of improving healthcare outcomes by
evaluating existing services that do not provide sufficiently
safe, effective or cost-effective care, and re-directing fund-
ing to services deemed superior against these criteria [3].
While disinvestment has been the focus of some interest
in nations increasingly oriented to healthcare system
sustainability, it has been operationalised only in min-
imal terms in a limited number of jurisdictions [4,5].
Complexities inherent in the identification of candidate
technologies and the specific application of disinvest-
ment criteria have curtailed efforts to establish clear
procedures that may engender change and withstand
political challenge. More broadly, the inherently ethical
nature of disinvestment decision-making has raised
questions as to the appropriate inputs required to sup-
port such processes [6,7]. Increasing agreement that
stakeholder input is required for disinvestment pro-
cesses to be representative and accountable has also
complicated the establishment of pragmatic mecha-
nisms for disinvestment [8,9].
Notes on the Australian policy context
At the national (Medicare) level in Australia, a review
process of existing health care services funded via Medicare,
has been established under the responsibility of the Depart-
ment of Health, including the Medical Services Advisory
Committee (MSAC), which makes recommendations to
the Health Minister about what medical services offer
sufficient safety and (cost)effectiveness to warrant public
subsidy. Since 2009, a ‘Quality Framework for Australia’s
Medicare Benefits Schedule’ has been developed whereby
individual health care practices face review as to their
appropriateness for continued public subsidy at current
levels. Potential outcomes from a review include: an
amendment to the item description such that it better
captures the patient group/s most likely to benefit from
any procedure; an increase, decrease or maintenance of
the fee; or a complete stop to public funding of the item
[3,10]. The present study is aligned within this general
policy context.
With these concerns in mind, the present study de-
velops and tests a model whereby different forms of
evidence are incorporated into a disinvestment policyprocess. More specifically, we sought to operationalise a
potential disinvestment policy model incorporating evi-
dence of safety and effectiveness, a comparison of policies
from a range of jurisdictions, ethical and cost analyses and
the informed deliberations of stakeholders with regard
to a specific case-study technology: assisted reproduct-
ive technologies (ART) with a particular focus on differ-
ential effectiveness by age.
ART – a case study
Australians utilise a high number of ART cycles per mil-
lion population when compared to other countries –
partly the result of essentially unlimited public subsidy
for ART services (a contrast to many other similarly
developed countries). Australians are eligible for this
subsidy regardless of their age or any prior treatment
attempts. However, as ART in Australia are offered
primarily through the private sector, there remains a
patient-borne ‘gap’ payment beyond what Medicare (the
nation’s universal health insurance scheme) will subsidise.
Once a patient’s out-of-pocket expenses reach a threshold
amount in any given year, any further gap payments are
covered by government through a Safety Net program.
The combination of these factors has led to significant
cost escalations for Medicare (tax-payers). Hence, the
public subsidy of ART has been a perennially conten-
tious health policy issue in Australia. The Australian
government – regardless of the party in power at the
time – has periodically entered into policy debates around
access criteria for ART services (a situation mirrored in
the international experience) for more detail see [11,12].
Assisted reproductive technologies (with a particular
focus on the impact of maternal age and number of cy-
cles on treatment cost and effectiveness) were selected
as a potentially useful case study on which to trial an
engaged disinvestment process – for two reasons. First,
ART meet multiple criteria on a proposed framework
for identifying disinvestment candidates [9]: there exists
substantial temporal and geographic variation in ART
treatment provision, in addition to evidence of differential
effectiveness across patient sub-groups [11]. Second, as
introduced above, considerable public debate and lobby
group opinion in relation to previous government-mooted
subsidy restrictions in Australia [11,12] suggest that ART
represents fruitful ground for analysis of the social and
ethical evidence needed to inform a representative dis-
investment decision.
In light of these reasons, and to incorporate the differ-
ent forms of evidence flagged by them, a dual approach
to data generation was adopted in this study. First, a
systematic review assessed evidence of differential ART
safety and effectiveness according to maternal age, pater-
nal age and number of treatment cycles [11]. This review
was supplemented by an analysis of ethical considerations
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ART effectiveness and maternal age [13] and the in-
corporation of a recent Australian analysis of ART cost-
effectiveness by maternal age and number of treatment
cycles [14]. In turn, this evidence base informed delib-
erative forums attended by vested stakeholders (ART
clinicians and consumers) as well as by non-partisan
citizens. Guided by the ideals of deliberative democracy,
these forums involved the provision of detailed informa-
tion to support participants’ deliberation on the ques-
tion of how best to structure the public funding of ART,
and were designed to elicit colloquial and experiential
knowledge to enhance the structured evidence base arising
from the review and supplementary analyses.
Deliberative processes are underpinned by the theory
that an appropriately informed sample of the population
can deliberate productively with a view to offering
contributions to policy development that are reflective
of broader values. Used productively in other contexts
to canvass community and stakeholder perspectives
on health-related priority setting [15-17], deliberative
methods are held to both improve and legitimate policy
directives [18]. In the context of disinvestment decision-
making where, it may be argued, there is a particular
imperative for “health services to be accountable to
users as taxpayers, voters and consumers” [19], delib-
erative methods represent a more transparent means of
addressing the complex, ethical nature of resource allo-
cation and policymaking.
In this paper we outline the findings of stakeholder
engagements that sought to incorporate technical, ex-
periential and colloquial evidence within a hypothetical
disinvestment context. In doing so, we propose a disinvest-
ment model that stands to enhance more conventional
evidence-based policy with informed stakeholder engage-
ment to support ethical, democratic health governance.
Methods
Below is a summary of the methods employed in this
study. A detailed account of the research process is pub-
lished elsewhere [6].
Evidence generation
The first phase of the project entailed conducting a sys-
tematic review of ART [11]. This review utilised contem-
porary health technology assessment methods and policy
processes, as appropriate for the Australian context. The
protocol was assessed by content experts, and focussed
on evidence of effectiveness associated with maternal
age and number of treatment cycles. Key outcomes of
the systematic review included findings that ART effect-
iveness decreases with advancing maternal age (noting a
particular decrease after age 42) and that, across all age
groups, ART effectiveness decreases slightly with eachsuccessive cycle of treatment. These findings were con-
sistent with the economic analysis consulted [14], which
found that the cost-effectiveness of ART decreases with
both treatment cycle number and, in particular, female
age. An ethical analysis was conducted to canvass fur-
ther relevant considerations. It described different pos-
sible conceptions of medical need as well as different
respects in which these frameworks, as well as treatment
effectiveness and maternal age, could be considered rele-
vant to ART funding policy [13,20].
Deliberative engagements
In the second phase, the evidence generated was pre-
sented at a series of deliberative stakeholder engage-
ments held in Adelaide, South Australia with groups of
ART clinicians, non-partisan citizens and ART con-
sumers (past patients). Each stakeholder group attended
two engagement sessions (two ‘rounds’ of engagements
spaced a number of weeks apart) in which they were
asked to deliberate on the evidence presented, and to
generate (and justify) a preferred approach to the public
subsidy of ART in Australia1. These engagements incor-
porated key elements of deliberative methods, including
the provision of accessible information by content ex-
perts, facilitation by an independent professional, small
and larger group deliberation and the generation of pol-
icy guidance [21].
An outline of the evidence described above was pre-
sented at each engagement by the research team, who
then remained in attendance to clarify technical and fac-
tual issues as they arose. Participants were also pre-
sented with an outline of the approach to ART funding
currently operating in a range of other national contexts
including Israel, Canada, Denmark and the UK. The fund-
ing structure applied in New Zealand was also presented,
generating discussion around that country’s use of subsidy
criteria which include a potential patient’s age, body mass
index (BMI) and smoking status [22].
In light of the information presented, participants were
asked to consider the question: Should the criteria for pub-
lic funding of ART be changed? If yes, why? If no, why not?
Each group was also encouraged to address broader issues
around the barriers and facilitators to disinvestment and
the (potential) role of stakeholders within both ART and
health policy decision-making, more broadly.
In the second round, outputs from all first round en-
gagements (i.e. the perspectives of each stakeholder group)
were reported to all participants and allowed to inform
their subsequent deliberations.
The decision to separate stakeholder groups supported
participants to voice partisan opinions freely, without fear
of the impact of different degrees of expertise [23]. At the
same time, the ‘feeding back’ of other groups’ deliberative
outputs brought together a range of (potentially conflicting)
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vant policy advisors for consideration.
Recruitment
A detailed account of the recruitment process is outlined
elsewhere [6]. Participants in the consumer forums were
purposively recruited on the basis of relevant experience;
9 participants attended Round 1 and 7 returned in Round
2. Community forum participants were randomly sampled
(stratification criteria included gender, age and household
income) and 14 attended Round 1 while 10 returned for
Round 2. Clinician participants were purposively recruited
on the grounds of relevant technical experience and as
nominees from relevant medical bodies; 8 attended Round
1 while 6 returned for Round 2.
While the sample size for the community engagements
was within the range deemed ideal for citizens’ juries
[25,26], the consumer and clinician forums were slightly
smaller owing to the specificity of recruitment require-
ments (including selection criteria designed to minimise
potential harm to past patients). Nonetheless, the sample
sizes allowed for fulsome deliberation around a variety
of inputs and opinions, and for active participation in
“communicative processes and will formation” [27].
The project received ethics approval from the University
of Adelaide’s Human Research Ethics Committee. Partici-
pants were assured that their contributions to deliberations
would remain anonymous, and that they were at liberty to
withdraw their participation at any time. Consent for an
experienced stenographer to transcribe deliberations was
obtained from all in attendance, and an honorarium was
paid to participants at the conclusion of each forum.
Approach to data analysis
Transcripts of the deliberative forums were analysed the-
matically [28,29]. Given the project’s dual focus on the
specific case of ART, and broader questions around ap-
proaches to disinvestment, analysis attended to both the
deliberative and analytical outputs of the engagements
[30]. That is, we aimed to represent the content of each
deliberation, while engaging with the broader policy im-
plications of the perspectives articulated.
Analysis of each group’s deliberations is presented separ-
ately to illustrate areas of within-group disagreement and
consensus. To highlight pervasive themes, we attend to
participants’ responses to questions concerning (1) the key
values that should inform potential ART subsidy restric-
tions, and (2) whether it would be appropriate to restrict
subsidies on the basis of personal patient characteristics
(including BMI, smoking status, maternal age, or number
of treatment cycles). Participants’ perspectives on patient
contributions to the cost of ART treatments are also ad-
dressed and insights applicable to broader disinvestment
questions are considered.Results
Consumers
Values underpinning arguments for and against subsidy
restrictions
It might have been expected that consumers of ART –
particularly those whose treatments resulted in success-
ful live births – would be ‘protective’ of funding in this
area, and reluctant to see restrictions applied in a do-
main with such personal resonance [31]. However, delib-
erations in the consumer forum were characterised by
strong agreement that health resources are limited, and
that some subsidy restrictions may therefore be justified
in the area of ART, particularly when advancing maternal
age significantly reduces the likelihood of positive treat-
ment outcomes. Participants across the group recognised
the finite nature of health resources (“We’re not a bottom-
less pit”– Linda) and demonstrated a nuanced under-
standing of the notions of both ‘opportunity cost’ (“I think
you can’t fund everything, you have to have criteria” –
Kate) and ‘capacity to benefit’ (“I wouldn’t expect the gov-
ernment to give me three fully funded [ART treatment]
cycles with my chances so small” – Kylie). There was
agreement across the board that these concepts were
highly relevant to public subsidy decisions.
Questions around the status of ART as a “want or a
need” also informed – and polarised – the subsidy de-
bate. On the one hand, the depiction of ART as a non-
essential ‘choice’ supported calls for subsidy reductions
and increased patient contributions to treatment costs.
LARA: You just save, save, save to accomplish what
you want because … it’s the difference between a want
and a need.
RITA: I don’t think the government should entirely
fund all of it because … we’ve all got a medical
condition, that’s why we’re into IVF, but it’s more a
case of personal wanting … It’s not that you have a
heart condition and you need that to live.
On the other hand, the notion that people do not
‘choose’ infertility repositioned ART as a medical ‘need’
that should be funded like any other.
DEANNE: [Subsidy restrictions are] completely
horrifying because I didn’t choose my situation.
DAWN: If somebody has a mental health condition, do
we only support them to get better if they meet certain
criteria, or do we say this person has a need … we need
to match the health provision with the medical need?
Despite this debate, there was broad agreement that
any kind of restriction to ART subsidies should be based
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in the absence of scientific ‘facts’, were pervasively de-
nounced as ‘arbitrary’ and therefore insupportable.
PAULINE: You can’t come up with an arbitrary figure
and say [age] 43 or 45, it should have evidence behind it.
DEANNE: If it’s not backed up by scientific facts and
proof, then I feel really, really resentful that a
government is going to make a decision on whether
I’m a mother or not. I find that arrogant.
‘Medical evidence’ with regard to treatment effectiveness
was depicted as distinct from ‘clinical judgement’. While
ART consumers supported the use of clinical effectiveness
data in informing subsidy schedules, they were more re-
served in their endorsement of ‘medical opinion’ as a basis
for funding limitations. While these arguments were pri-
marily proffered on the grounds of “transparency”, there
was also concern that a blurring of clinical judgement and
doctors’ interests may not always encourage prudent
financial, or emotional, investment.
PAULINE: Any sort of restriction should be
scientifically based. [A test of ovarian reserve], maybe
something like that. I think it puts a restriction on it for
funding and it also gives the women a bit more insight
and transparency and is not giving them false hope.
Restrictions based upon patients’ social/moral characteristics
Participants in this forum suggested that no access to sub-
sidised cycles of ART should be allowed for current drug
users or people who have been convicted of child abuse.
Beyond these specific concerns, the ART consumer forum
did not support the introduction of subsidy restrictions
based upon patients’ social or moral characteristics. While
discussion of ‘patient worthiness’ was evident, this theme
generally did not appear in accounts arguing for the exclu-
sion of ‘undeserving’ consumers. Only one participant sug-
gested that issues of choice reduce worthiness (“I felt guilty
accessing it because my partner had chosen prior to me, hav-
ing a vasectomy” – Kate), while another argued that already
having children (seen as a choice after having ‘met the need’
to be a mother) could be a legitimate grounds for restriction.
More frequently, (often autobiographical) accounts of
patients who had ‘taken responsibility’ served to legitimate
continued public expenditure on ART for those who have
‘done their part’ within the reciprocal taxpayer contract.
DEANNE: I have worked hard for this country and
worked hard for this State. I’m a little bit pissy I’m
paying so much [referring to co-payments]… My BMI
was low and I’d never smoked, never drank. I kind of
felt like “I have done my part. You do your part”.Restrictions based upon age and treatment cycle number
The consumer forum agreed to outer female age limits
for ART treatment subsidies: no access under 21 or over
45. This agreement was reached in the second engage-
ment session after lengthy discussion in the first as to
whether age 42 might be an appropriate ceiling (interest-
ingly, at least three participants were approximately this
age when they received ART treatment).
Ultimately, the forum reached its strongest agreement
around the notion that ovarian reserve (in conjunction
with other physiological markers of likely treatment
effectiveness) is the most appropriate basis for limiting
subsidy, and preferable to limits based upon age or
cycle number. This agreement was underpinned by the
understanding that such policy decisions should be both
‘individualised’ and ‘grounded in medical evidence’.
JOHN: I think you have to assess case by case and say
“Look, what [are] the health issues, what is the ability
of the person to have a baby”.
While essentially representing a ‘capacity to benefit’
argument (“the ability of a person to have a baby”), such
accounts called for more nuanced restrictions than
blunter, age-based limitations. However, although these
arguments appeared to place considerable decision-
making responsibility in the hands of clinicians, partici-
pants were keen to hold doctors’ powers in check.
DEANNE: There has to be some … medical ethics
involved here [because] they’re benefiting from you
being a repeat client.
Although most participants’ arguments in favour of
restrictions emphasised the capacity to benefit and issues
of financial prudence (the notion that it is a ‘bad invest-
ment’ when a patient’s likelihood of success is low), one
participant suggested that age limits could have additional
benefits with regard to patients’ psychological ‘closure’.
DEANNE: I think people need to have some closure
point, I think that is psychologically important, and
that it would be better put to bed if there’s scientific
fact based on that closure point rather than a
government saying “This is your closure point
because we are the government of the day”.
Restrictions based upon BMI/smoking status
Discussion of the funding model operating in New Zealand
at the time the forums were held focused on the legitim-
acy of limiting ART subsidies on the grounds of BMI
and smoking status.
The recurring theme of ‘taking responsibility’ informed
arguments in the consumer forum in favour of limiting
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pose risks to the success of their treatment. Once again, a
reciprocal construction of health expenditure was evident:
DAWN: [The funders] could be saying “We’ve done
our part, what have you done? You’re smoking, you’re
overweight, your BMI is through the roof. You are a
huge risk to us as a success”
DEANNE: If it’s going to be publicly funded I think
the client has a responsibility to play their part in the
success of the fertility treatment.
More commonly, however, accounts advocating limits
based upon smoking status and BMI oriented to the
likelihood these factors will reduce treatment success, or
pose risks to the unborn child.
KATE: [It shouldn’t be about] discriminating because
you are a smoker or obese, but that your chances of
getting pregnant because you are obese or a smoker
are much less than if you were not.
RITA: There [are] statistics to say you are affecting
your baby. You may not, but the statistics say that
your baby can be affected.
Although limitations based upon BMI and smoking sta-
tus were broadly accepted, there was concern that such re-
strictions might unfairly discriminate against those facing
issues ‘beyond their control’. The dominant concern that
patients ‘take responsibility’ was circumvented in accounts
of circumstances in which BMI or smoking were deemed
beyond a patient’s full responsibility or power to change.
KYLIE: I think you have to be careful that it’s not seen
as a form of discrimination … there are conditions
that cause them to be overweight not by their own
actions or choice.
A more explicit depiction of obesity and smoking as
‘medical problems’ supported arguments against such
restrictions, allowing the invocation of ‘slippery slope’
arguments (“Ethically, I mean do we stop operating on
people who are overweight for other things?” – Kylie)
and eventual agreement that weight control and smoking
cessation support should become part of ART treatment
programs, rather than serve as criteria for entry into them.
The issue of co-payment
The consumer forum achieved a consensus opinion that
patients should (continue to) contribute a co-payment
for their ART treatment. This position was informed
by the pervasive emphasis on ‘taking responsibility’, andlinked to the (minority, but repeated) opinion that ART
represents a ‘choice’.
KATE: We weren’t rich, we worked hard. It’s your
choice.
A pervasive concern that treatment options should be
equitable led many in the forum to advocate a means
test for co-payments (namely, that a patient’s contribu-
tion should be relative to their capacity to pay).
PAULINE: We’d be setting out babies only for the
rich.
Eventually, broad agreement was reached that a pro-
hibitive blanket cost is unjust and unsupportable if it
puts ART beyond the reach of many.
KYLIE: It’s unfair just because you are not in a good
job or a white collar job that you’re punished, that
you can’t access these services.
Community
Values underpinning arguments for and against subsidy
restrictions
While the consumer forum emphasised notions of pa-
tient ‘responsibility’, the community forum was charac-
terised by the perspective that the health care system
must ensure the needs of all patients are met. Only one
participant questioned the appropriateness of subsidising
ART per se (“A child is a gift … [infertility is] the num-
bers you draw sometimes” – Roger); beyond this there
was broad agreement that infertility represents a need
that should be funded “like any other medical condition”
(Ron).
Participants were particularly concerned that subsidy
restrictions may be gender discriminatory given that
contradictory workplace and fertility imperatives put
women in “an impossible situation” (Martha) with re-
gard to the timing of conception and childrearing.
There was also general agreement that all infertile pa-
tients should be able to access ART treatments, and
that wealth should not be a barrier in this regard:
MARTHA: You are either infertile or not. Whether
they are rich infertile or poor infertile I think they
should be on the same level.
Restrictions based upon patients’ social/moral
characteristics
Participants unanimously agreed that no access to subsi-
dised ART treatments should be allowed for convicted
paedophiles, and all but one participant agreed that con-
victed child abusers should be similarly excluded. It was
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allowed to appeal their restriction on the basis of miti-
gating circumstances (e.g. number of years clean).
Beyond these issues, two divergent opinions emerged
(and were not reconciled) in the community forum
around whether it would be appropriate to restrict
ART subsidies with regard to patients’ social and moral
characteristics. One group of participants indicated a
willingness to “screen” ART recipients to ensure that
their treatment is being sought “for the right reasons”
(Esther).
CURTIS: Some parents aren’t necessarily having
children for wholesome reasons and [maybe] there
can be some sort of screening around that, particularly
if the baby bonus outweighs the costs of the IVF.
One participant introduced the notion that character-
istics of the children resulting from ART may (or may
not) justify the costs of their conception.
DOUG: It doesn’t work because what you get at the
end, assuming this person goes to work which is no
guarantee, there’s no guarantee that person will go to
work and pay taxes … so you have these resources
going in and no guaranteed income at the end of it.
Another group of participants voiced strong rebuttal
to these perspectives, arguing the abhorrence of policy
grounded in subjective valuations of prospective parents
or children.
SARAH: Who in their right mind could price a child
or anybody’s life? … [We] do not get to decide who is
more valuable, who is not. We all eat, we all go to the
toilet, we all breathe, we all contribute in some way to
society. How do we get to decide that? Why should
governments play God?
Restrictions based upon age and cycle number
Participants in the community forum agreed upon an
upper age limit of 45 years and a lower age limit of 18
years for subsidised ART treatment. More restrictive
limits on the basis of maternal age and number of cycles
generated considerable debate, a pervasive perspective
being that treatment decisions should be “individualised”
rather than being based upon population statistics.
RON: I think it’s a very individual issue about whether
the treatment can be deemed to be appropriate for
the patient, not based on statistics.
After much deliberation, and confirmation from the
researchers in attendance that most patients do notattempt more than seven treatment cycles, a majority of
participants agreed that patients should be able to access
a maximum of ten subsidised cycles. This framework
was subsequently refined, and broad agreement emerged
that an appropriate structure would allow five subsidised
cycles per live birth up to a maximum of two children
born of IVF. Within this model, a majority of partici-
pants supported a limit of two treatment cycles for pa-
tients over the age of 40, given that after this point the
likelihood of treatment success “drops off so much”
(Curtis).
The notion of outcome probabilities also informed
questions (ultimately unresolved) around potential ex-
ceptions to the proposed limit of two subsidised cycles
after the age of 40. A question arose as to whether it
might be more appropriate to subsidise more than two
cycles for women over 40 who had already had a child
on the grounds that selection bias suggests they are
“a more reliable bet”. Conversely, a question also arose
as to whether extra cycles for women over 40 should be
limited to those who had not yet had success, on the
grounds that they faced greater need.
Restrictions based upon BMI/smoking status
Community forum members demonstrated more openness
to subsidy restrictions based upon BMI and smoking status
than either consumers or clinicians. Concern around
‘singling out’ART for restriction on these grounds was a
minority opinion in this context.
ANNIE: What about heart disease? We all know we
should exercise and not smoke, and yet we still keep
funding for [that].
More commonly, willingness to restrict on age and
smoking was justified and supported on a variety of
grounds. For example, one participant emphasised the
general importance of (prospective) mothers ‘taking
responsibility’.
MEGAN: What I like about [restricting on these
grounds] is the fact there is some input from the
mother, she can’t just sit back and expect it all to
happen to her, she has to make an effort.
More pervasive justifications rested on the impact of
smoking and obesity on the likelihood of treatment suc-
cess and on the health of the unborn child.
ALLAN: the smoking part of it, we know that makes
a pretty dramatic impact on their ability to carry to
term, the health of the child, even after the child has
been born, passive smoking around the child, I think
for me that would be a gateway hurdle.
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lated in economic terms:
CURTIS: We all know that for a smoker it increases
the risk of a deformed pregnancy … that it is going to
be more public money that’s going to have to go into
that and this is a risk we could actually stop now by
not allowing the IVF.
The forum agreed that they would support restrictions
for current smokers and patients whose BMI indicates
they are obese, with the option for patients to “appeal to a
board” if their obesity reflects exceptional circumstances.
It was noted, however, that an appeals board could, in
itself, represent an economic burden (“The board might
cost you more than the funding would” – Esther).
The issue of co-payment
It was broadly agreed that co-payments for ART treat-
ments should be retained. For some participants, a co-
payment was deemed an important means of encouraging
earlier, unassisted reproduction in the wider population as
opposed to ‘reliance’ on ART.
MARTHA: [T]o encourage people that may have the
potential for fertility as they are younger but not as they
get older, I think there should be a co-payment.
For others, co-payments represented a means of proving
one’s commitment to having a child and one’s responsibil-
ity as an aspiring parent.
MEGAN: If they want it badly enough, they should be
making some kind of contribution.
Arguments emphasising dis/encouragement, personal re-
sponsibility and the concern with ‘equity’ coloured the debate
around how a co-payment schedule should be structured.
As deliberation progressed, ‘responsibility’ arguments sup-
porting calls for a co-payment on all cycles gave way to con-
cern that the prohibitive nature of any co-payment might
reduce equity of access. After canvassing a ‘safety net’ option
(the suggestion that patients stop being required to make
a co-payment once they have reached a certain level of
expenditure), for which there was majority agreement, nine
out of ten participants agreed to a participant’s proposal that
patients be given two treatment cycles free of charge, then
charged a co-payment for subsequent cycles. This proposal
was seen to encourage both equity of access and patient
responsibility. In turn, this payment structure was argued to
encourage earlier natural reproduction (to avoid later-cycle
co-payments) and to make ART accessible to younger infer-
tile couples who would not have to delay treatment while
saving for their co-contribution.Clinicians
Values underpinning subsidy/coverage restrictions
Clinicians’ deliberations centred on accounts highlight-
ing the significance of ART outcomes (see [32] for a
complete account of clinicians’ deliberations around evi-
dence of ART effectiveness). There was strong agreement
that ART funding should be approached ‘no differently to
the funding of treatment for any other medical condition’,
given the comparable benefits.
GEOFF: [Deliberations about the funding of] ART still
is based on a concept that it’s not as serious as cancer
or Alzheimer’s or whatever.
While only one clinician mobilised the language of
‘rights’ to advocate for ART funding (“The ability to
reproduce is a basic human right” – Helen), all partici-
pants emphasised the significance of ART outcomes as a
more than adequate return on a funding investment.
Supported by the underlying value that health funds
should not be wasted, clinicians argued the superior util-
ity of ART funding in comparison to other areas of
health expenditure.
GEOFF: It’s a very interesting exercise to count the
loss of QALYS2 if there is insufficient fertility
treatment [and] if you take that seriously compared to
many parts of medicine, there should be a big
increase in funding for fertility service[s].
Concern around the potentially discriminatory implica-
tions of ART restrictions also coloured clinicians’ delibera-
tions. Clinicians emphasised a need to protect themselves
in this regard (with regard to age limits, doctors “do get
cases taken to antidiscrimination all the time” – Jane), and
the implications for women more generally (“The 50-60
year old husband of a much younger second wife, and
he’s had his vasectomy and he’s now perfectly able to
come along and have IVF treatment without anyone
arguing about it but his 45 year old ex-wife is not able
to” - Helen).
Restrictions based upon patients’ social/moral
characteristics
Clinicians did not deliberate extensively around this issue.
One clinician raised concerns about a 50-year-old parent’s
capacity “to run around” after their seven-year-old child,
but the majority would not countenance the notion of
socially-derived restrictions.
Restrictions based upon age and cycle number
Once again, concern around discrimination (specifically
framed in terms of unequal access to significant, life-
changing technology) underpinned deliberations. Like the
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the need for individualised assessment rather than the
local application of population statistics.
HELEN: I take every person on face value and
individual characteristics. To put these markers on it
is dangerous when you talk about individuals.
In general terms, the clinicians rejected calls for blan-
ket age or cycle limits. However, there was agreement
that ovarian age would represent a more legitimate basis
for restrictions than chronological age, if limitations
were deemed necessary.
HELEN: I replace age with fertility ovarian reserve
assessment. [It’s] a more inclusive assessment of
chance of success rather than just a blanket age.
While deliberations were coloured by broad agreement
that the ‘art of medicine’ is paramount in this domain
(‘I would hate to have laws dictating what we can and
can’t do in this area’), one clinician was in favour of an
explicit upper age limit. A desire for an externally im-
posed justification for not subsidising ‘futile treatment’
underpinned this position:
JANE: I would like Medicare to tell us that [45 is the
limit]; not saying no, they can fully fund it themselves.
ARTHUR: Why 45?
JANE: It’s futile treatment.
Restrictions based upon BMI and smoking status
Deliberations around the legitimacy of restricting on
‘lifestyle factors’ were particularly heated in the clini-
cians’ forum.
Some participants argued in favour of women being
required to “correct the correctable” (reducing BMI, smok-
ing cessation) before ART. While framed in terms of costs
and benefits, these arguments emphasised a need to act in
the best interests of the child while also maximising the
likelihood of treatment success.
JULIA: The chances of an IVF cycle succeeding in
somebody who is currently smoking is 50% compared to
a non-smoker. Should they not be responsible to society
and the taxpayer and stop smoking for two reasons: to in-
crease their chances of pregnancy for themselves and so-
ciety and to increase the wellbeing of their unborn child?
For one participant, explicit restrictions in this regard
were framed as a means of ‘backing up a doctor’s call’ in
cases where clinicians are cognisant of the likely impact
of obesity or smoking yet feel unable to refuse treatment
on these grounds.JANE: Part of me would like the idea ‘the computer
says no’ and you have to go and lose some weight.
Strong objections were levelled at each of these argu-
ments by other forum members. For several clinicians,
concerns with such restrictions were practical: BMI and
smoking status were depicted as arbitrary measurements
that may bear no relation to potential treatment outcomes.
HELEN: [BMI and smoking] are arbitrary
characteristics about human beings… If you are a
smoker with an obstructed fallopian tube, why is the
smoking causing you not to get pregnant?
For others, a deeper ethical concern around ‘punishing
people for their lifestyle’ underpinned their position, which
was bolstered by a depiction of obesity and smoking as
‘medical disorders’ only partly within a person’s control.
GEOFF: I [think] very much in principle that people
should have exactly the same healthcare. …So far in
healthcare we have never prejudiced people for their
lifestyle. … BMI is increasingly recognised as a
medical disorder which is only partly under control of
people. We never apply the principle: “Oh you’re too
big, you are not going to have surgery at all”. That is
really shaking the foundation of how we provide
healthcare.
Fears that restrictions of this kind would unfairly ‘sin-
gle out’ ART treatments prompted participants to draw
comparisons with other areas of healthcare expenditure
and to invoke the ‘slippery slope’ of limiting medical
subsidies on the basis of lifestyle ‘choices’.
JANE: You can relate that back to the $1.3 billion
being spent on statins to lower cholesterol. Will we say
“stop eating the high cholesterol food?”. Don’t spend
the $1.3 billion because you want to eat prawns?
GEOFF: Basically the neurosurgeon across the street
[could] say “We’re not going to treat your brain
haemorrhage because you were speeding”. That’s the
slippery slope.
While pervasive concern was voiced around the ‘un-
fairness’ of restricting on these grounds for ART alone
(“[That] would be all very well if every other medical
intervention had the same criteria applied to it” –
Helen), others countered that such restrictions do (per-
haps quite rightly) apply.
LYDIA: [T]here are some other situations where they
do take that into account; for example transplantation
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may not get your heart transplant.
Debate was intense, and involved a range of competing
conceptions of the costs and benefits (medical, social
and moral) of restricting treatment subsidies on the
basis of ‘lifestyle factors’.
The issue of co-payment
All participants agreed that ART patients should con-
tinue to be responsible for a financial co-contribution.
There was broad consensus that co-payments represent
a means of ensuring that patients ‘value’ the service
provided.
RANDAL: As soon as it’s completely free, it’s often
not valued.
JULIA: It’s abused.
At the same time, the clinicians agreed that access to
ART should be ‘equitable’, a value that underpinned
calls for a co-payment structure to reflect prospective
patients’ capacity to pay. Only one participant argued
that a universal co-payment supports equality because
‘everyone is treated the same’. All others advocated
a co-payment structure whereby contributions are
means tested, or linked to one’s financial capacity, so
that treatment does not become beyond the reach of
many.
RANDAL: It’s equitable, everyone gets a shot.
HELEN: They don’t … They don’t all get a shot.
GEOFF: The top end [do]
LYDIA: Some people do not get the shot.
Concern around the prohibitive nature of co-payments
(“There are people who would not dream of it because
they don’t have the money” – Geoff ) and the lack of
opportunity for lower income patients to seek fully
funded treatment in a public environment ultimately
led the forum to advocate for one free treatment cycle
for those with demonstrated need.
HELEN: We are saying the icing on the cake would
be to add in the possibility of a cycle for those who
really can’t afford it.
To summarise the outcomes discussed in this section,
the general position reached by each stakeholder group
is represented in the table below.Discussion
In combination, the outcomes of these deliberative
engagements represent an informative contribution to
funding policy debates in this arena. Our results in-
form the application of this engagement method, (a) in
disinvestment deliberations generally, and (b) specifically
in terms of ART, including suitability of the method for
contested (ethical) domains.
Firstly in relation to general contributions, it was clear
that all participants understood the finite nature of health
funding, and the notion that difficult decisions must be
made when treatment costs expand within a context of lim-
ited resources. This underscores a key tenet of deliberative
democracy: that all citizens, when provided with sufficiently
detailed background material, can participate thoughtfully
and meaningfully in the process of policy formation [27].
More significantly, it was evident that participants were
open to genuine consideration of funding options that did
not always align with their own interests. The willingness of
ART consumers and clinicians to countenance restrictions,
and for community members cognizant of ‘opportunity
costs’ to be open to continued expenditure, speaks to the
capacity of invested stakeholders in taking up the challenge
of deliberative democracy [33]. Reductionist, deterministic
characterizations of stakeholder ‘self-interest’ proved un-
founded as each group sought to prioritise universal values
(in particular, ‘equity’ and ‘responsibility’) over specific,
within-group concerns. This result has significance, as pre-
viously it has been documented that decision-makers reveal
an inclination to shy away from disinvestment decisions
due to their allotting weight to the voices of resistant, vocal
minorities [12]. Our results suggest such weighting to be
disproportionate to the broader stakeholder response and
incongruent with an aversion to act based on perceived risk
of stakeholder backlash.
With ART forming the background context, numerous
outcomes were necessarily ART specific. Yet agreement on
a range of broad values was evident across the engage-
ments, and these have implications for the transferability
and applicability of this method beyond ART. As we have
shown, each forum emphasized a need for subsidy restric-
tions to be ‘grounded in medical evidence’ rather than gov-
ernmental decree. Interestingly, population-based medical
evidence of a drop in treatment effectiveness with advan-
cing maternal age (suggesting the potential usefulness of an
age-based subsidy restriction) was somewhat undermined
by another shared value: the importance of individualizing
treatment decisions. A pervasive feature of contemporary
health discourse [34], this latter principle underscored the
preference of the consumer and clinicians’ forums that any
potential restriction to be based upon (individual) physio-
logical markers rather than maternal age or cycle number.
Future research could elucidate the practicality of this sug-
gested approach by outlining the state-of-the-science
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markers, and asking, for instance, whether test accuracy is
superior to age in predicting ART prognosis.
On the controversial topic of whether BMI and smoking
status represent legitimate grounds for subsidy restrictions,
not one forum reached consensus. In each group, concerns
around fairness (‘singling out’ ART; punishing people ‘for
their lifestyle’) came up against concerns around ‘maximis-
ing treatment effectiveness’ and ‘the best interests of the
child’. These principles are applicable within ART and
beyond. The fact that the deliberations of each group were
so similar underscores the capacity of ‘lay’ people to con-
tribute to the ethical aspects of health policymaking [35].
Despite disparate levels of technical knowledge, the groups
were similarly equipped to engage with the social and moral
complexities of restricting on these grounds.
The importance of canvassing different groups of stake-
holders separately [23] also became evident when differ-
ences across the groups were observed. For example, while
the clinicians agreed that infertility should be treated ‘no
differently than cancer’, both the consumer and community
groups engaged in heated debate on this issue – debate that
may have been less freely expressed in the presence of med-
ical experts. Similarly, while the community and clinician
groups argued that the ‘judgment of doctors’ should be
paramount in decisions regarding likely treatment effective-
ness, consumers were less deferential, emphasizing a need
for guidelines to ensure that doctors are ‘transparent’ about
costs and likely outcomes. Again, such resistance to whole-
sale ‘doctor deference’ may have been expressed less expli-
citly in the presence of clinicians.
Ultimately, each stakeholder forum reached a different
decision as to their preferred ART funding structure,
emphasizing different guiding principles (See Table 1). For
the consumer group, an outer limit of 45 years with means-
tested co-payments represented a model informed by con-
cern with the financial aspects of the ART journey, and a
unique framing of an ART age cut-off as important for
psychological ‘closure’. For community members, a limit to
the subsidized funding of 5 cycles per child (up to a max-
imum of two children), restrictions on smoking and BMI
(with room for appeal) and two free cycles with co-
payments required thereafter, arose within an oftenTable 1 The ART public funding arrangements commended b
Age limit Cycle limit
Consumers No publically subsidized





access <18 or >45 and;
limit of 2 cycles >40
5 cycles per child to
max. 2 children
Clinicians No publically subsidized
access >45
-genuinely hypothetical deliberation process that attended to
ethical issues around equity of access, opportunity cost and
capacity to benefit. The clinicians’ model, advocating the
continuation of co-payments with the addition of a free
cycle for those unable to pay, also oriented to equity of
access, their desire for a mandated age ceiling (45) argued
to support them in ‘making their call’(i.e. to deny ART
treatment on grounds of medical futility).
As these outcomes illustrate, all stakeholder groups advo-
cated in favour of patient co-payments for ART treatment
programs, which may reflect the broader experience
Australians have with co-payments across the health
care system. This compares to the findings of Rauprich
[31] whose survey canvassed patient and professional
opinions on the financing of ART in Germany. In that
study, co-payments for ART were deemed acceptable by
only one-third of patients, two-thirds of ART physicians
and three-quarters of other groups (including academics,
social lawyers and health politicians). Among these
groups, a preference for full public subsidy was strongly
correlated with the conceptualization of infertility as ‘a
disease’ or ‘medical need’. Our findings contrast with
those of Rauprich et al., in that our patient and clinician
participants, who most frequently framed infertility as an
issue of ‘medical need’, were as supportive of continued
co-payments as members of the broader community.
More noteworthy is the finding that each forum explicitly
incorporated into their preferred funding arrangement
policy elements aimed at increasing equity of access. Again,
although this principle was articulated specifically for ART
it may well be a broader concern. While the policy
elements differed from group to group, this finding echoes
concerns noted elsewhere [31,36] that co-payments cur-
rently do, but ought not to, put ART out of the reach of the
less affluent. This consensus is indicative of a concern not
currently addressed in the Australian context, namely that
access to fully subsidised ART treatment within the public
system is severely limited and co-contributions for private
patients are not differentiated by income.
In terms of the full range of opinions regarding ART
subsidies, our study was limited to the extent that all
participants in the consumer forum had been successful in
their ART journey; for ethical reasons we did not recruity different stakeholders
Other restrictions Payment structure
- Means-tested co-payment
for all cycles
Current smokers; BMI in obese
range (option to appeal); Convicted
paedophiles, child abusers; Illicit
drug users
2 free cycles; co-payment
on subsequent cycles
- Co-payment for all cycles;
option of free cycles for
those unable to pay
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informed by ethical and cost analyses, as well as studies of
treatment effectiveness, but did not draw media represen-
tations of ART (arguably an important informant of public
discourse on this topic) into the discussion (for analysis on
this element see Street et al [12]). However, by involving
a range of stakeholders including ‘average taxpayers’, a
group rarely canvassed within health policy development
[26], this study indicates important possibilities for ensur-
ing accountability in the health policymaking process – a
particularly important concern in the context of what
are largely ethical decisions.
Selecting ART as a case study was strategic given the
ethically charged nature of the debate in Australia and else-
where. The engagement sessions proved highly instructive,
with outcomes being relevant for ART specifically, but also
in capturing underlying principles that have broader rele-
vance in disinvestment decision-making. It has been argued
that, for disinvestment decisions, a different level of
evidence is required than that required for investment, in
large part because of the social and/or political baggage
involved in ‘taking something away’ [7,10,37]. Indeed, the
nature of such decision-making may also require different
kinds of evidence than those typically incorporated, namely
the qualitative, experiential, socially-negotiated evidence
that is attainable using deliberative methods and that may
have a central role to play in the future of disinvestment
policymaking. The ART evidence base, in terms of safety
and effectiveness, is relatively well dotted with signposts
from which to navigate a debate on these complementary
qualitative, experiential matters. Not all existing health care
services are as well informed, so it may be that a yet-
unknown threshold of safety/effectiveness evidence is
required such that productive engagement at this level is
possible. Where the technical evidence is relatively robust,
our results highlight that democratically informed disinvest-
ment decision-making is feasible. In addition, it is revealed
that such decisions could be potentially less controversial
than often presumed [11,12,22], including for such highly
ethically charged cases as ART.
Conclusion
Deliberative processes, engaging key stakeholders including
citizens, in decision making around potential disinvestment
from low value health care, provides an avenue for contribut-
ing to policy making in a contentious area of health policy.
Endnotes
1Through its universal health insurance program,
Medicare, the Australian Government provides one of the
world’s most comprehensive subsidization programs for
ART procedures, for all citizens and permanent residents.
Co-payments are generally required.
2Quality adjusted life years, a measure of disease burden.Competing interests
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